|

Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China

RECRUITINGSponsored by Wuxi Hisky Medical Technology Co Ltd
Actively Recruiting
SponsorWuxi Hisky Medical Technology Co Ltd
Started2022-07-01
Est. completion2023-06-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05597709

Summary

In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes
* UAP were measured based on iLivTouch
* Willing to attend this study and able to provide the written informed consent.

Exclusion Criteria:

* Other types of diabetes
* Patients unable to receive regular follow-up

Conditions4

DiabetesLiver DiseaseMetabolic Associated Fatty Liver DiseaseType 2 Diabetes Mellitus in Remission

Browse More Trials

Diabetes trialsLiver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.